Vietnam's in vitro diagnostics (IVD) market is continuing its steady expansion as healthcare providers invest in modern laboratory technologies to improve disease detection, patient outcomes and clinical efficiency. Rising healthcare awareness, an ageing population and increasing prevalence of chronic and infectious diseases are creating sustained demand for advanced diagnostic solutions across the country.
According to IMARC Group, Vietnam's in vitro diagnostics (IVD) market reached US$349.3 million in 2025 and is projected to grow to US$503.6 million by 2034. Growth is being supported by government investment in healthcare infrastructure, technological innovation and expanding access to diagnostic services.
In vitro diagnostics refers to medical tests performed on samples such as blood, urine or tissue outside the human body to detect, diagnose and monitor disease. Modern IVD technologies support the diagnosis of infectious diseases, cancer, cardiovascular disease, diabetes and many other conditions, enabling clinicians to make faster and more accurate treatment decisions. The market includes immunodiagnostics, molecular diagnostics, haematology, clinical chemistry and tissue diagnostics.
Several structural trends are accelerating growth across Vietnam:
- Growing awareness of the importance of preventive healthcare and early disease detection.
- Increasing incidence of chronic diseases including diabetes, cardiovascular disease and cancer.
- Continued investment in hospital laboratories and diagnostic infrastructure.
- Expansion of molecular diagnostics and precision medicine.
- Rising demand for rapid diagnostic and point-of-care testing.
- Growth in medical tourism, increasing demand for high-quality laboratory services.
- Adoption of automation, artificial intelligence and digital laboratory management systems.
Molecular diagnostics continues to be one of the fastest-growing areas within the IVD sector. According to IMARC Group, Vietnam's molecular diagnostics market reached US$108.5 million in 2025 and is forecast to grow to US$175.6 million by 2034, driven by increasing adoption of PCR, DNA sequencing and genomic technologies for infectious disease testing, oncology and genetic diagnostics.
Point-of-care testing is also expanding rapidly as healthcare providers seek faster diagnostic results closer to the patient. Vietnam's point-of-care diagnostics market reached US$230.5 million in 2025 and is expected to grow to US$465.4 million by 2034, reflecting increasing demand for decentralised testing in hospitals, clinics and community healthcare settings.
Cancer diagnostics represents another major growth area. IMARC Group estimates Vietnam's cancer diagnostics market reached US$887.2 million in 2025 and is forecast to grow to US$1.60 billion by 2034, underlining the growing importance of advanced diagnostic technologies in supporting earlier detection and personalised cancer treatment.
Technological innovation continues to transform the diagnostics landscape. Laboratories are increasingly adopting automated analysers, laboratory information management systems (LIMS), artificial intelligence, digital pathology and next-generation sequencing to improve throughput, accuracy and workflow efficiency. These technologies are helping healthcare providers deliver faster diagnoses while supporting the shift towards precision medicine and personalised healthcare.
Leading global companies including Roche Diagnostics, Abbott, Siemens Healthineers, Danaher (Beckman Coulter and Cepheid), Thermo Fisher Scientific, bioMérieux, Sysmex, QIAGEN, Bio-Rad Laboratories and Becton Dickinson (BD) continue to expand their diagnostic portfolios across Vietnam, introducing advanced laboratory systems, molecular testing platforms and AI-enabled diagnostic solutions.
As Vietnam continues to modernise its healthcare system and strengthen laboratory capacity, the in vitro diagnostics market is expected to remain a cornerstone of the country's healthcare transformation. For suppliers of diagnostic instruments, reagents, laboratory automation, molecular diagnostics and digital pathology technologies, Vietnam represents one of Southeast Asia's most attractive long-term healthcare investment opportunities.